LGND News and Press, Ligand Pharmaceuticals Incorporated From 05/16/23

Study achieves primary endpoint, demonstrating statistically significant reductions in liver fat from baseline to week 12 in patients receiving VK2809 as compared to placebo Ligand is entitled to receive a $10 million milestone payment upon initiation of a Phase 3 clinical trial as well as ro...

2023-05-04 22:49:14 ET Ligand Pharmaceuticals Incorporated (LGND) Q1 2023 Results Conference Call May 04, 2023 04:30 PM ET Company Participants Simon Latimer - Head of Investor Relations Todd Davis - Chief Executive Officer Tavo Espinoza - Chief Financial Office ...

2023-05-04 17:01:56 ET Ligand Pharmaceuticals press release ( NASDAQ: LGND ): Q1 Non-GAAP EPS of $2.28 beats by $1.39 . Revenue of $43.9M (+20.3% Y/Y) beats by $10.35M . For further details see: Ligand Pharmaceuticals Non-GAAP EPS of $2.28 beats by $1.39,...

2023 Financial Guidance Raised Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates. Ligan...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report first quarter 2023 financial results after the close of the U.S. financial markets on Thursday, May 4, 2023, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general ...

2023-03-25 10:30:03 ET Summary Ligand’s strategy of providing development capital to high-quality assets with capable teams is paying off, as evidenced by the recent positive developments and advancements in its product pipeline. Ligand Pharmaceuticals has recently announce...

Prospective screening of subjects for ESR1 mutations will use the Guardant360 CDx blood test for companion diagnostic development Phase 3 study is supported by previously presented ELAINE-1 and ELAINE-2 Phase 2 study results Sermonix anticipates dosing the first patient in first...

ST. LOUIS, March 06, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast and gynecological cancers harboring ESR1 mutations, today announced that its lead drug candidate, ...

Ligand Pharmaceuticals, Inc. (LGND) Q4 2022 Earnings Conference Call February 22, 2023 04:00 PM ET Company Participants Simon Latimer - Head, IR Todd Davis - CEO Tavo Espinoza - CFO Matthew Korenberg - President and Chief Operating Officer Conference Call Par...

Ligand Pharmaceuticals press release ( NASDAQ: LGND ): Q4 Non-GAAP EPS of $1.36 beats by $0.24 . Revenue of $50.38M (-10.7% Y/Y) beats by $10.75M . Now expect 2023 royalties of $74 million to $78 million (previously $72 million to $76 million), sales of Captisol of $21...